pharmaceuticals industry l.
Skip this Video
Loading SlideShow in 5 Seconds..
Pharmaceuticals Industry PowerPoint Presentation
Download Presentation
Pharmaceuticals Industry

Loading in 2 Seconds...

play fullscreen
1 / 15

Pharmaceuticals Industry - PowerPoint PPT Presentation

  • Uploaded on

Pharmaceuticals Industry. Cogent and Pharmaceuticals . Pharmaceutical Industry. Pharmaceutical Industry: “Traditional” branch Research = Discovery: new “small” organic molecules (years) Deep competence in drug discovery via Organic Chemistry

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

Pharmaceuticals Industry

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
pharmaceuticals industry

Pharmaceuticals Industry

Cogent and Pharmaceuticals

pharmaceutical industry
Pharmaceutical Industry
  • Pharmaceutical Industry: “Traditional” branch
      • Research = Discovery: new “small” organic molecules (years)
      • Deep competence in drug discovery via Organic Chemistry
      • Development: pre-clinical & clinical testing and approval (10 years)
      • Commercialisation (during Patent lifetime; 20 years)
      • Issues: regulations & approvals; high drug attrition rate; manufacturing costs; national markets e.g., NHS; pipeline value- innovation; international competition incl. Emerging markets
  • Bio-Pharma: Non-”traditional” branch
      • Very large biological molecules-bio-pharmaceuticals (nucleic acids, proteins)
      • Fundamental understanding of human biology and diseases: R&D cutting edge: Big Science
      • Many SMEs and micros: start-ups, University spin-offs
      • Cash short; risky: Survival!!
      • But no escape from long timescale to commercialisation: technical and commercial symbiosis with traditional Pharma
pharmaceuticals uk
  • Largely SE, NW and NE England
      • £12bn exports; trade balance £3.5bn
      • 73,000 direct employees (27,000 in R&D); 250,000 related employees
      • £3.2 bn in UK-based R&D (25% of UK total R&D in manufacturing)
      • ~100 UK companies producing prescription medicines
      • UK: 80% all GP prescriptions written generically
      • Third most profitable UK , after tourism and finance
sector skills councils
Sector Skills Councils
  • Cogent footprint: “SIC Codes”
      • Manufacture of basic pharmaceutical products (24.41 {03}; 21.10 {08})
      • Manufacture of pharmaceutical preparations (24.42; new 21.20)
  • SEMTA: “Science” (not SIC based)
      • Research and Development
      • Bioscience
      • {There will now be (08) a R&D SIC 72.11 (bio) & 72.19 (Eng & Science)}
  • Other SSCs:
      • Skills for Health -pharmacy
      • Lantra -Animal Technologists
      • Improve – Food Technologists
      • SSDA –Pharmaceutical packaging
cogent going forward
Cogent going forward
  • Re-licensing in 2008:
      • Rationalise the Science-Pharma and Bio-pharma interface
  • Post Leitch Review of UK Skills:
      • Cogent the only body to determine vocational Qualifications eligible for funding: Qualifications valued by employers
      • Sole “owner” of National Occupation Standards (NOS)
      • Sole owner of Apprenticeship Standards
  • National Skills Academy for the Processing Industries
  • Higher Education:
      • Emerging and critical area for SSCs generally
current skills situation in pharmaceuticals
Current Skills Situation in Pharmaceuticals
  • Skills Gaps at Levels 2 to 4
      • Gaps = employee not fully proficient in current job role
      • Particular issue with Process and Plant Operatives roles
      • First line maintenance
      • Lean manufacture and continuous improvement
      • Rapid manufacture techniques
      • Basic chemistry/understanding of processes
      • Application of knowledge, including graduates’ practical and interpretative skills
current skills situation in pharmaceuticals7
Current Skills Situation in Pharmaceuticals
  • Skills Shortages
      • Vacancies hard to fill due to lack of suitable candidates
      • Especially Level 4+, graduates in chemical and molecular biological sciences
      • The “omics” technologies; synthetic organic chemistry; clinical R&D
      • University courses declining in relevance
      • Analytical chemistry
      • ABPI Report: Sustaining the Skills Pipeline in the Pharmaceutical and Biopharmaceutical Industries;
cogent process industries economic value of skills
Cogent Process Industries – Economic Value of Skills

Source: DBERR, Value-Added Scorecard, 2007

  • Skills Intensity* Process Industries
    • High : Medium-High
    • c.f. Banking : Life Insurance
    • *measured as average employee cost
  • Skills and Productivity
  • Basic skills - employment
  • Medium skills (FE/HE) - productivity
  • Higher skills (HE) - sustainability

Process Industry - in transition:

  • Value Added
  • Speciality Products
  • Process/Product Innovation
  • R&D
demographics skills education and training
Demographics, Skills, Education and Training
  • Leitch (2006/2007)
  • UK target as world leader in skills
  • SSCs as regulators of vocational FE
  • Close collaboration between SSCs and HE

Education Headlines

  • 70% of 2020 workforce already >16 yrs of age
  • 12% decline in 18 yr olds 2010- 2020
  • 40% jobs will require graduate skills by 2020
  • 90% of 2+ A’L student in HE (50% Voc Quals)
  • UK 11 out 30 (OECD) attainment at Level 4
  • FE to have FD-awarding status
  • all 16-18 yr olds to be in educ OR training?
pharma s response
Pharma’s Response
  • Response part of overall business requirements/pressures
      • Costs; international competition; M&A; licensing, regulatory, etc
      • Large organisations becoming leaner, flatter
      • Less middle-management, more empowered, higher-skilled operational and technical workforce needed
      • Majors have tradition of in-house training
      • Small and micro companies: rely on Higher Education; other methods poorly utilised
  • Other options are to recruit from immigrant population or move manufacturing and/or R&D abroad
industry response c t d
Industry Response, c’t’d
  • Pharma companies and their Trade Associations are engaging with the public skills infrastructure-however it’s cluttered and complicated!
      • Schools, Colleges- out-reach and influencing teaching and content
      • HE: notoriously tough to change their cultures
      • Regional and national entities: RDAs, Business support networks, Government agencies such as Learning and Skills Councils
  • Self-organised networks are addressing, inter alia skills
      • E.g., ABPI nationally; NEPIC in NE; Biopharma and Health Technologies Employer Consortium in SE
      • Networks are of variable strength regionally; many quite lean
      • Networks want joined-up offering from all providers and agencies
cogent s role
Cogent’s role
  • In-depth projects, based on deep knowledge of vocational (and soon higher education) provision and mechanisms, to understand and develop solutions for Pharmaceutical and Bio-pharma employers, employees and education and training providers
      • including close collaboration with SEMTA and fdf
    • The existing workforce: demographics are: 75% of today’s workforce will still be employed in 2010
      • Cogent Gold Standard for up-skilling the existing pharmaceutical workforce
    • Entering workforce:
      • Apprenticeship framework (Level 3)
      • Career pathways: attraction of talent from school age onwards
      • Higher Education: Level 4+
        • Foundation degrees, articulated to Honours Degrees
        • New Cogent team for Higher Education in 2008
cogent s role c t d
Cogent’s role- c’t’d
  • Vocational Qualifications: understanding employer needs and translating into qualifications that employers value
      • Relevant: practical skills combined with underpinning knowledge
      • Progressive: life-long learning and upskilling
      • Flexible (modular) provision at work and in classroom
      • Secure funding from Government for Cogent-approved qualifications
      • Articulation to honours degree via Foundation Degrees
  • National Skills Academy for Process Industries
      • Quality assure provision of all training products and qualifications
      • Meet individual employers’ individual needs
      • Shared Skills Needs Database with Cogent for continuing relevance of all training and education of pharmaceutical employees
  • Skills Brokerage Service: First point of call for any employer
      • Train to Gain; BIT; but not only these- skills diagnosis and sign-posting to all provision